Theravance Biopharma, Inc. (TBPH)
NASDAQ: TBPH · Real-Time Price · USD
16.23
+0.97 (6.36%)
At close: Mar 31, 2026, 4:00 PM EDT
15.91
-0.32 (-1.97%)
After-hours: Mar 31, 2026, 4:16 PM EDT
Theravance Biopharma Stock Forecast
Stock Price Forecast
The 5 analysts that cover Theravance Biopharma stock have a consensus rating of "Buy" and an average price target of $17.8, which forecasts a 9.67% increase in the stock price over the next year. The lowest target is $14 and the highest is $24.
Price Target: $17.8 (+9.67%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Theravance Biopharma stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 3 |
| Buy | 0 | 0 | 1 | 1 | 1 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 5 | 5 | 5 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| TD Cowen | TD Cowen | Hold Maintains $13 → $15 | Hold | Maintains | $13 → $15 | -7.58% | Mar 23, 2026 |
| BTIG | BTIG | Strong Buy Reiterates $21 | Strong Buy | Reiterates | $21 | +29.39% | Mar 20, 2026 |
| Oppenheimer | Oppenheimer | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Mar 5, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $27 → $15 | Strong Buy | Maintains | $27 → $15 | -7.58% | Mar 4, 2026 |
| B. Riley Securities | B. Riley Securities | Strong Buy → Hold Downgrades $28 → $14 | Strong Buy → Hold | Downgrades | $28 → $14 | -13.74% | Mar 4, 2026 |
Financial Forecast
Revenue This Year
117.68M
from 107.46M
Increased by 9.51%
Revenue Next Year
90.37M
from 117.68M
Decreased by -23.21%
EPS This Year
0.96
from 2.06
Decreased by -53.21%
EPS Next Year
-0.05
from 0.96
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 193.5M | 98.7M | |||
| Avg | 117.7M | 90.4M | |||
| Low | 80.4M | 83.3M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 80.1% | -16.2% | |||
| Avg | 9.5% | -23.2% | |||
| Low | -25.2% | -29.2% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 1.37 | 1.44 | |||
| Avg | 0.96 | -0.05 | |||
| Low | 0.19 | -0.87 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -33.7% | 49.2% | |||
| Avg | -53.2% | - | |||
| Low | -91.0% | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.